President Trump has for now suspended a 25% levy on imports from Canada, but the looming tariff threat was a hot topic of discussion at a life sciences summit in Toronto.
CEO David Ricks in a Thursday earnings call touted the $23 billion Lilly has spent on expanding its manufacturing capabilities to meet the growing demand for its GLP-1 drugs.